AO

Rua Life Sciences PLCFRA Rua Life Stock Report

Last reporting period 31 Mar, 2024

Updated 13 Nov, 2024

Last price

Market cap $B

0.01

Micro

Exchange

XFRA - Deutsche Boerse AG

AOHA.F Stock Analysis

AO

Uncovered

Rua Life Sciences PLC is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-19/100

Low score

Market cap $B

0.01

Dividend yield

Shares outstanding

22.185 B

RUA Life Sciences Plc is a holding company, which engages in the commercialization of biomedical polymer technology, components, and medical devices. The company is headquartered in Ayrshire, Ayrshire and currently employs 38 full-time employees. The Company’s principal activities comprise exploiting the value of its intellectual property (IP) and know-how, medical device contract manufacturing and development of cardiovascular devices. The firm operates through four businesses, which include RUA Medical, RUA Biomaterials, RUA Vascular and RUA Structural Heart. Its RUA Medical business provides sub-contract manufacturing, assembly, packing and services to the medical device sector from its class seven and eight cleanroom suites. Its RUA Biomaterials is the depository of the IP and licensing rights to a range of biostable, implantable polymers, including Elast-Eon and ECSil. Its RUA Vascular business is the legal manufacturer and IP holder of the Company’s cardiovascular and soft tissue patches and bore vascular grafts. Its RUA Structural Heart business holds the intellectual property relating to the Company’s synthetic heart valve technology.

View Section: Eyestock Rating